NEW YORK — Oncolytics Biotech Inc. (NASDAQ:ONCY) disclosed accelerating enrollment in its pivotal randomized trial REO 033 evaluating pelareorep in combination with FOLFIRI and Roche’s (OTCQX:RHHBY) marketed anti-VEGF monoclonal antibody bevacizumab for second-line treatment of RAS-mutant, microsatellite stable (MSS) metastatic colorectal cancer. This disclosure, detailed in Exhibit 99.1 to Oncolytics’ September 28, 2026 Form 8-K filing with the U.S. Securities and Exchange Commission (accession 0001129928-26-000057), confirms that substantially all planned Part A clinical sites were active and that multiple patients had been enrolled. The company expects sufficient evaluable enrollment by the end of October to support an interim clinical update by year-end 2026. With a primary endpoint of objective response rate (ORR), REO 033’s randomized design contrasts with historical nonrandomized observations from Oncolytics’ prior REO 022 study, which reported a 33% ORR and median progression-free and overall survival markedly longer than benchmarks, though cross-trial comparisons preclude definitive conclusions on treatment advantage.
The significance of Oncolytics’ evolving REO 033 program extends beyond the immediate clinical data readout into broader sector dynamics and institutional positioning within oncology drug development pipelines. Roche’s bevacizumab, integral to both arms of the REO 033 trial, remains a cornerstone anti-angiogenic agent approved for metastatic colorectal cancer but faces pressure as the sector targets molecularly defined populations and improved efficacy. Importantly, Roche is pursuing regulatory approval for Tecentriq (atezolizumab) in the adjuvant setting for stage III mismatch repair deficient (dMMR) and microsatellite instability-high (MSI-H) colon cancer, a distinct population from Oncolytics’ second-line RAS-mutant, MSS focus. Roche’s pending FDA target action date for this indication is scheduled for October 9, 2026, underscoring the company’s broader multi-modal immuno-oncology approach in colorectal cancer that diverges from Oncolytics’ viral immunotherapy platform combined with chemotherapy and targeted agents.
Novartis (NYSE:NVS), meanwhile, provides a relevant comparator within the oncology sector given its diversified portfolio and sustained growth driven by targeted therapies such as Kisqali in breast cancer and Pluvicto in prostate cancer. Although Novartis lacks a second-line RAS-mutant MSS colorectal cancer program analogous to Oncolytics’ REO 033, its robust oncology revenue and pipeline emphasize strategic balance between pioneering investigational therapies and marketed assets across several tumor types. This diversification reduces dependence on a single indication or modality, highlighting an operational contrast to Oncolytics, which remains heavily invested in progressing pelareorep through key clinical inflection points. Despite no head-to-head competition or overlapping indication, Novartis’ oncology franchise performance reflects sector-wide institutional interest in cancer therapeutics innovation, which indirectly influences investor sentiment and capital allocation toward smaller, more speculative entities such as Oncolytics.
From a capital markets perspective, Oncolytics’ ability to advance REO 033 amid an increasingly selective funding environment for mid-stage oncology trials will be closely watched. The design of REO 033, targeting approximately 60 randomized patients in Part A and potentially expanding in Part B to support accelerated regulatory pathways based on ORR, mirrors the high-risk, high-reward dynamic present in clinical-stage biopharma investing. Investors assessing ONCY’s positioning must weigh the absence of reported efficacy data in the randomized setting to date, the caveats around cross-study historical data, and the timing of potential interim results. Conversely, Roche’s embedded position via bevacizumab and its impending regulatory decision for Tecentriq reveal a mature, multi-indication approach that influences how institutions might hedge oncology exposure between early developmental assets and established franchises. Novartis represents a further anchor point reflecting sector-wide momentum driven by precision oncology and multiple, ongoing label expansions.
Institutional positioning in ONCY, RHHBY, and NVS stocks is thus shaped by differing risk profiles and timelines. ONCY’s near-term catalyst hinges on data maturity and enrollment milestones that will clarify pelareorep’s additive value in a stubborn immunotherapy-resistant subset of metastatic colorectal cancer. RHHBY’s share performance is increasingly linked to Roche’s advancing IMpassion-like immuno-oncology programs and maintenance of bevacizumab franchise leadership amid biosimilar competition. NVS, underpinned by a diversified oncology pipeline, benefits from more predictable revenue streams but remains attentive to competitive pressures and the need for innovation, all of which determine capital flows within the sector.
Looking ahead, the next several months will be critical for Oncolytics as it approaches the evaluable patient threshold for interim REO 033 assessment, with potential regulatory implications if Part B is pursued for accelerated approval pathways. This phase will test the durability of institutional interest amid broader macroeconomic headwinds impacting clinical-stage biotech valuations. Meanwhile, Roche’s imminent FDA decision on Tecentriq in earlier-stage colon cancer will further define competitive dynamics in immuno-oncology, influencing investor risk appetite and strategic allocations across colorectal cancer portfolios. Novartis’ continued oncology revenue growth underlines the value of diversification in navigating sector volatility. Collectively, the developments at ONCY, RHHBY, and NVS illustrate the nuanced interplay between clinical progression, regulatory trajectories, and institutional capital deployment shaping the oncology pharma landscape in late 2026.
Sources:
Oncolytics Biotech Form 8-K (September 28, 2026), Exhibit 99.1
Oncolytics Biotech press release, GlobeNewswire, September 28, 2026
https://www.globenewswire.com/news-release/2026/09/28/3369944/0/en/oncolytics-biotech-reports-accelerating-enrollment-in-randomized-reo-033-ras-mutant-mss-colorectal-cancer-study.html
Roche product and regulatory information:
https://www.roche.com/solutions/pharma/productid-d263d2d3-708f-4fbd-87da-23364b2958f6
https://www.roche.com/media/releases/med-cor-2026-06-11
Novartis Q2 2026 oncology results and overview
https://prod1.novartis.com/sites/novartis_com/files/q2-2026-media-release-en.pdf
https://www.novartis.com/about/therapeutic-areas/oncology
Spotrate NewsDesk
